Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Furiex Rises on FDA Approval of Takeda Diabetes Medicine

Jan. 28 (Bloomberg) -- Furiex Pharmaceuticals Inc. rose the most in more than two years after partner Takeda Pharmaceutical Co. won U.S. regulatory approval for a new diabetes treatment.

Furiex rose 66 percent to $35.34 at 4 p.m. New York time, in its biggest gain since June 2010. Takeda, based in Osaka, Japan, advanced 1.4 percent to 4,615 yen at the close of Tokyo trading, the highest since December 2008.

The Food and Drug Administration cleared Takeda and Furiex’s alogliptin and two combinations of the treatment to use with diet and exercise for patients with Type 2 diabetes. Morrisville, North Carolina-based Furiex said in a statement that it will receive a $25 million payment as a result of the approval as well as royalties based on U.S. sales.

“Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control,” the FDA said Jan. 25 in a statement.

The approval gives Takeda a new revenue source as cheaper generics erode earnings from Actos, its largest sales contributor and once the world’s biggest diabetes drug. Takeda, whose application for alogliptin was twice rejected by the FDA, has projected net income would fall to a 13-year low of 120 billion yen ($1.3 billion) in the 12 months through March 2015. The company said it plans to sell the medicines beginning in mid-2013.

Sales Peak

Actos sales peaked in the year ended March 2011 at $4.5 billion for Takeda and accounted for 27 percent of the company’s revenue at the time.

Alogliptin is in the same class of drugs as Merck & Co.’s Januvia, which generated $3.3 billion in 2011, and Bristol-Myers Squibb Co.’s Onglyza, which sold $473 million that year, according to data compiled by Bloomberg.

The first rejection of alogliptin came in June 2009, when the FDA said clinical data was insufficient based on new guidelines on diabetes treatments and cardiovascular risks released in December 2008. Takeda conducted additional studies for its resubmission. In April last year, the FDA asked for more information on the use of the medicine in other countries.

In the U.S., 25.8 million children and adults, or 8.3 percent of the population, have diabetes, including 7 million people who are undiagnosed, according to figures from the American Diabetes Association’s website.

Diabetes is caused by the body’s inability to use or produce the hormone insulin. It can lead to heart disease, kidney failure, blindness or amputations. Most diabetics have the Type 2 form linked to being overweight or inactive.

Alogliptin is approved in Japan and sold under the brand name of Nesina. The tablets will go by the same name in the U.S. The other products will be called Oseni and Kazano, Takeda said in the statement.

To contact the reporters on this story: Anna Edney in Washington at aedney@bloomberg.net Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.